hit counter
BiondVax Pharmaceuticals Ltd. (BVXV) Stock News Sentiment & Price - Sentifly
BVXV - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



BiondVax Pharmaceuticals Ltd. (BVXV)

Israel
Biotechnology
NASDAQ
BVXV Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BVXV Latest news
PRNewsWire
Neutral
BiondVax advances its growth strategy towards a new pipeline based on innovative VHH antibodies
2021-10-19 07:53

JERUSALEM, Oct. 19, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced the signing of a term sheet that includes binding financial terms of contemplated definitive agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.

PRNewsWire
Neutral
BiondVax Announces Second Quarter 2021 Financial Results and Provides Business Update
2021-08-26 16:05

JERUSALEM, Aug. 26, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its second quarter financial results for the quarter ended June 30, 2021.

PRNewsWire
Neutral
BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update
2021-06-23 06:00

JERUSALEM, June 23, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its first quarter financial results for the quarter ended March 31, 2021.

PRNewsWire
Neutral
Letter from BiondVax's New CEO to Shareholders
2021-03-23 07:44

JERUSALEM, March 23, 2021 /PRNewswire/ -- Dear Shareholders, After many years of pharmaceutical leadership positions in the US and Europe, I jumped at the opportunity to return to my roots in Israel to take over the reins as BiondVax's CEO. Since my appointment was announced in January, I had been wrapping up my role as Head of Global Vaccines Engineering, Core Technologies, and Asset Management at GSK Vaccines headquarters in Belgium.

PRNewsWire
Neutral
BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering
2021-02-10 16:30

JERUSALEM, Feb. 10, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced...

PRNewsWire
Neutral
BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering
2021-02-02 16:30

JERUSALEM, Israel, Feb. 2, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today...

PRNewsWire
Neutral
BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares
2021-01-29 07:57

JERUSALEM, Jan. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced...

PRNewsWire
Neutral
BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares
2021-01-28 18:48

JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced...

PRNewsWire
Neutral
BiondVax Announces Third Quarter 2020 Financial Results & Business Update
2021-01-28 15:23

JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced...

PRNewsWire
Neutral
BiondVax Announces Appointment of Amir Reichman as New CEO
2021-01-21 07:15

JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment of infectious diseases, today announced the appointment of Amir Reichman as its new CEO....

Loading more news...